ES2091757T3 - Agonistas y agonistas parciales del neuropeptido y. - Google Patents

Agonistas y agonistas parciales del neuropeptido y.

Info

Publication number
ES2091757T3
ES2091757T3 ES89115469T ES89115469T ES2091757T3 ES 2091757 T3 ES2091757 T3 ES 2091757T3 ES 89115469 T ES89115469 T ES 89115469T ES 89115469 T ES89115469 T ES 89115469T ES 2091757 T3 ES2091757 T3 ES 2091757T3
Authority
ES
Spain
Prior art keywords
agonists
neuropeptide
partial
npy
antagonics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89115469T
Other languages
English (en)
Inventor
John L Krstenansky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2091757T3 publication Critical patent/ES2091757T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

ANTAGONICOS DE NPY LOS CUALES SON DERIVADOS DE NPY NATURALES. EL ANTAGONISTA SE CONFIRMA USANDO LIGANTES COMPETITIVOS CONVENCIONALES Y MUESTRAS BIOQUIMICAS Y TAMBIEN SE DESCRIBE EL USO DE ESTOS DERIVADOS EN UNA VARIEDAD DE CONDICIONES EN LAS CUALES ESTA IMPLICADA LA NEUROPEPTIDA Y.
ES89115469T 1988-08-26 1989-08-22 Agonistas y agonistas parciales del neuropeptido y. Expired - Lifetime ES2091757T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23759188A 1988-08-26 1988-08-26

Publications (1)

Publication Number Publication Date
ES2091757T3 true ES2091757T3 (es) 1996-11-16

Family

ID=22894367

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89115469T Expired - Lifetime ES2091757T3 (es) 1988-08-26 1989-08-22 Agonistas y agonistas parciales del neuropeptido y.

Country Status (17)

Country Link
EP (1) EP0355793B1 (es)
JP (1) JP2791955B2 (es)
KR (1) KR0149160B1 (es)
CN (1) CN1042155A (es)
AT (1) ATE140235T1 (es)
AU (1) AU618118B2 (es)
CA (1) CA1341336C (es)
DE (1) DE68926804T2 (es)
DK (1) DK420789A (es)
ES (1) ES2091757T3 (es)
FI (1) FI894006A7 (es)
HU (1) HU204852B (es)
IL (1) IL91395A0 (es)
NO (1) NO893430L (es)
NZ (1) NZ230384A (es)
PT (1) PT91538B (es)
ZA (1) ZA896376B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229283T2 (de) * 1991-11-06 1999-09-23 Garvan Institute Of Medical Research, Darlinghurst Humaner neuropeptid y-y1 rezeptor
JPH08501055A (ja) * 1991-12-19 1996-02-06 ガーヴァン インスティチュート オブ メディカル リサーチ 神経ペプチドチロシンの生物学的機能を抑制する新規な分子
AU662032B2 (en) * 1991-12-19 1995-08-17 Garvan Institute Of Medical Research A novel molecule which inhibits neuropeptide tyrosine biological function
GB9213215D0 (en) * 1992-06-20 1992-08-05 Wellcome Found Peptides
CA2165200A1 (en) * 1993-06-18 1995-01-05 Ambikaipakan Balasubramaniam Neuropeptide y antagonists and agonists
US5516653A (en) * 1993-12-28 1996-05-14 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof
US5545549A (en) 1994-02-03 1996-08-13 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
US5989920A (en) * 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
AUPN646795A0 (en) 1995-11-09 1995-11-30 Garvan Institute Of Medical Research Neuropeptide Y-Y5 receptor
DE19652033A1 (de) * 1996-12-13 1998-06-18 Irmgard Dr Med Guertner Neuropeptid (CGRP) als Modulator zur Zelldifferenzierung und Proliferation
US6713265B1 (en) 1997-06-04 2004-03-30 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
WO2004098591A2 (en) 2003-05-05 2004-11-18 Probiodrug Ag Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
AU2004290499C1 (en) 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
CA2554809C (en) 2004-02-05 2014-04-29 Probiodrug Ag Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
CN111494606B (zh) * 2020-04-24 2021-12-14 广州医科大学 神经肽y的新应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3811193A1 (de) * 1988-04-01 1989-10-19 Boehringer Ingelheim Kg Neue peptide, verfahren zu ihrer herstellung und diese peptide enthaltende pharmazeutische zusammensetzungen

Also Published As

Publication number Publication date
EP0355793A2 (en) 1990-02-28
EP0355793A3 (en) 1992-04-22
AU4082889A (en) 1990-03-01
JP2791955B2 (ja) 1998-08-27
CA1341336C (en) 2002-01-29
DE68926804D1 (de) 1996-08-14
FI894006A0 (fi) 1989-08-25
AU618118B2 (en) 1991-12-12
CN1042155A (zh) 1990-05-16
NZ230384A (en) 1996-03-26
KR0149160B1 (ko) 1998-10-15
HU204852B (en) 1992-02-28
PT91538B (pt) 1995-05-04
FI894006L (fi) 1990-02-27
NO893430L (no) 1990-02-27
JPH02111794A (ja) 1990-04-24
ZA896376B (en) 1990-05-30
NO893430D0 (no) 1989-08-25
HUT50849A (en) 1990-03-28
DE68926804T2 (de) 1996-12-12
PT91538A (pt) 1990-03-08
DK420789D0 (da) 1989-08-25
EP0355793B1 (en) 1996-07-10
IL91395A0 (en) 1990-04-29
FI894006A7 (fi) 1990-02-27
KR900002799A (ko) 1990-03-23
ATE140235T1 (de) 1996-07-15
DK420789A (da) 1990-02-27

Similar Documents

Publication Publication Date Title
ES2091757T3 (es) Agonistas y agonistas parciales del neuropeptido y.
ES2061839T3 (es) Antagonistas del neuropeptido y.
DK385388D0 (da) Anvendelse af 5ht-3-antagonister
ATA222590A (de) Zementzusatzmittel
ES2085876T3 (es) Derivado de bifenilmetano, su utilizacion y composiciones farmacologicas que contienen el mismo.
DE3782999D1 (de) Bohrloch-zementierungszusammensetzungen.
DE3867594D1 (de) Zementzusammensetzung.
IT1183483B (it) Derivati di 1-fluorofenilbutil-4-(2-pirimidinil)fiperazina antipsicotici
DE3889284D1 (de) Zementzusammensetzungen.
ES2054045T3 (es) Benzodiazepinas, su procedimiento e intermediarios de preparacion y sus aplicaciones en terapeutica.
ES2023253B3 (es) Composiciones cementosas.
DE68910470D1 (de) Herstellung von Ligninsulfonat-Zusatzstoffen.
IT1203333B (it) Impiego di derivati del metilendiossibenzene con funzione sinergizzante in composizioni per uso insetticida
IT1240773B (it) Perfezionamento composizioni pozzolaniche.
ES2117654T3 (es) Antagonistas de colecistoquinina.
FI900490A7 (fi) Veteen dispergoituvat gemfibrotsiilikoostumukset
ES2057024T3 (es) Antagonistas de la neuroquinina a.
IT8722856A0 (it) Uso del trazodone
FI920423A0 (fi) Foerbaettringar i skaeranordning.
MX9204642A (es) 1,4-dihidropiridinas con actividad paf-antagonista
FI913881A7 (fi) Sementtikoostumus
SE8705060L (sv) Antiforkylningssats, antiforkylningspreparat och anvendning derav
IT1210482B (it) Composti analoghi della daunorubicina e della doxorubicina, loro preparazione ed uso.
KR900014278U (ko) 당구대용 포인트 눈금자
DE69008151D1 (de) Herstellung von dikationethern.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 355793

Country of ref document: ES